Žádné výsledky... Zkuste upravit dotaz a/nebo upravit či vypnout filtry.
Tukatinib
Dotaz
Zobrazit nápovědu
MeSH:
Pharmaceutical Vehicles-isolation & purification
MeSH:
Transcription Activator-Like Effector Nucleases-ultrastructure
MeSH:
Levorphanol-radiation effects
MeSH:
Eukaryotic Initiation Factor-4F-pharmacokinetics
MeSH:
MSX1 Transcription Factor-ultrastructure
MeSH:
vasotocin-moč
Autor:
Noè, Adele
MeSH:
HLA-DP antigeny-moč
MeSH:
Parotid Diseases-classification
MeSH:
deoxyribonukleasy-klasifikace
MeSH:
echolálie-virologie
MeSH:
maytansin
MeSH:
inhibitory beta-laktamasy
Nejvíce citované:
31427204
Nejvíce citovaný článek - PubMed ID 31427204
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
The Lancet. Oncology.
2019 Oct ;
20 (10) :
1370-1385.
[epub] 20190816
